2 most recent filings and news items mentioning RCKT. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/RCKT/news?limit=20"
Pull RCKT filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayRocket Pharmaceuticals reported that its RP-A501 gene therapy was well-tolerated with no significant safety concerns observed in three treated patients, leading the company to engage actively with the FDA on the next steps for the Phase 2 pivotal trial.
View filing at SEC.gov →Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in gross proceeds, increasing pro forma cash to approximately $322.6 million. The non-dilutive funding is expected to support operations into Q2 2028 and strengthens t
View filing at SEC.gov →